COMMUNIQUÉS West-GlobeNewswire

Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
12/03/2026
Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026 Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary cardiac endpoint [...]
Health Catalyst Reports Fourth Quarter and Year End 2025 Results
12/03/2026
SALT LAKE CITY, March 12, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported [...]
TerrAscend Reports Fourth Quarter and Full Year 2025 Financial Results
12/03/2026
Net Revenue of $66.1 million for Q4 2025 and $260.6 Million for FY 2025 Gross Profit Margin of 52.1% for Q4 2025 and 52.3% for FY 2025 from continuing operations Q4 2025 Net Cash provided from continuing operations of $ [...]
iSpecimen Launches AI Agent Revolutionizing Biospecimen Matching
12/03/2026
Strengthens iSpecimen’s next-generation marketplace platform Woburn, MA, March 12, 2026 (GLOBE NEWSWIRE) -- iSpecimen Inc. (the “Company”) (NASDAQ: ISPC) , a leading technology marketplace connecting researchers with [...]
VitalHub Announces Updated Date for Fourth Quarter and Annual 2025 Results
12/03/2026
TORONTO, March 12, 2026 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) announced today that it has updated the date for the release of its financial results for the fourth [...]
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
12/03/2026
First-in-class immune-stimulating antibody conjugate BDC-4182 in Phase 1 dose escalation study, initial clinical data expected in 3Q 2026 Cash balance of $31.8 million as of December 31, 2025 anticipated to fund key [...]
Cellectis publiera ses résultats financiers du quatrième trimestre et de l’année 2025 le 19 mars 2026
12/03/2026
NEW YORK, 12 mars 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa technologie pionnière d’édition du génome TALEN® pour développer [...]
Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
12/03/2026
– Announced FDA acceptance of NDA for lorundrostat in adults with hypertension; assigned PDUFA target date of December 22, 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., March 12, 2026 (GLOBE NEWSWIRE [...]
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
12/03/2026
ORKA-001 EVERLAST-A 16-week data now expected in 2Q 2026 following rapid enrollment, with longer-term follow-up data expected in 2H 2026 ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis initiated with data expected [...]
Iridex to Report Fourth Quarter and Full Year 2025 Financial Results on March 26, 2026
12/03/2026
MOUNTAIN VIEW, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for [...]
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
12/03/2026
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 12 mars 2026 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / Nasdaq Euronext [...]
Surgery Partners, Inc. Names Lloyd Dean to Board of Directors
12/03/2026
BRENTWOOD, Tenn., March 12, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”) recently announced that Lloyd Dean has been appointed to serve as an independent director [...]
CapsoVision to Release Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 26, 2026
12/03/2026
Conference Call Scheduled for Thursday, March 26, 2026, at 4:30 pm ET SARATOGA, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing [...]
Voting Rights and Shares Capital of the Company
12/03/2026
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, March 12, 2026 (GLOBE NEWSWIRE [...]
Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
12/03/2026
NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS, NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving [...]
Vaxart Provides Business Update and Reports Full Year 2025 Financial Results
12/03/2026
Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated early Q2 2026 Published positive clinical results in the first quarter of 2026 demonstrating oral norovirus vaccine candidate was [...]
Nephros Announces Fourth Quarter and Record Fiscal Year 2025 Financial Results
12/03/2026
Full-Year Net Revenue Increased 33% Y-O-Y to $18.8 Million and Fourth-Quarter Net Revenue up 22% Y-O-Y to $4.7 Million Reports Second Consecutive Year of Positive Net Income SOUTH ORANGE, N.J., March 12, 2026 (GLOBE [...]
Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results
12/03/2026
Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics Phase 1 monotherapy [...]
BioSyent Schedules Fourth Quarter and Full Year 2025 Earnings Release for March 19, 2026
12/03/2026
MISSISSAUGA, Ontario, March 12, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the fourth quarter and full year ended December 31, 2025 on [...]

Pages